Cardiotoxicity is a significant cause of pre- and post- approval drug failure.  The current dominant in vitro assay, the hERG channel assay, has limitations such as low detection rate and frequent false positives/negatives.  On the other hand, animal tests are costly and time consuming, but they might not be accurate models of human cardiomyocytes.  Ethical concerns of reliance on animal testing are also increasing.

A Cardiotoxicity assay using human iPS/ES cell-derived cardiomyocytes can be a better in vitro model, which overcomes the weaknesses of current cell-based assay and animal testing. ReproCELL has developed QTempo, which is a system to examine cardiotoxicity using human beating cardiomyocyte-like cells, based on cutting edge stem cell research and technology. InfiniteBio represents ReproCELL in North America, and has started providing services and products.